Aerken Maolake

Aerken Maolake

Auto-generated profile, based on publicly available information

Aerken Maolake

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAerken Maolake
Aerken Maolake
KIKouji Izumi
Kouji Izumi
KSKazuyoshi Shigehara
Kazuyoshi Shigehara
ANAriunbold Natsagdorj
Ariunbold Natsagdorj
HIHiroaki Iwamoto
Hiroaki Iwamoto
AMAtsushi Mizokami
Atsushi Mizokami
Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22CCR4 axis

25 March 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
AMAerken Maolake
Aerken Maolake
KIKouji Izumi
Kouji Izumi
ANAriunbold Natsagdorj
Ariunbold Natsagdorj
HIHiroaki Iwamoto
Hiroaki Iwamoto
SKSuguru Kadomoto
Suguru Kadomoto
AMAtsushi Mizokami
Atsushi Mizokami
Understanding the mechanism of lymph node metastasis, a poor prognostic sign for prostate cancer, and the further dissemination of the disease is important to develop novel treatment strategies. Recent studies have reported that C‐C chemokine receptor 7 (CCR7), whose ligand is CCL21, is abundantly expressed in lymph node metastasis and promotes cancer progression. TNF‐α is chronically produced at low levels within the tumor microenvironment. The aim of this study was to determine whether TNF‐α promotes prostate cancer dissemination from metastatic lymph nodes via activation of the CCL21/CCR7 axis. First, human prostate cancer cells were determined to express both TNF‐α and CCR7. Low concentrations of TNF‐α were next confirmed to induce CCR7 in prostate cancer cells through phosphorylation of extracellular signal‐regulated kinase. Finally, CCL21 was found to promote the migration of prostate cancer cells via phosphorylation of the protein kinase p38. Our results suggest that TNF‐α leads to the induction of CCR7 expression and that the CCL21/CCR7 axis may increase the metastatic potential of prostate cancer cells in lymph node metastasis.

13 November 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
ANAriunbold Natsagdorj
Ariunbold Natsagdorj
KIKouji Izumi
Kouji Izumi
KHKaoru Hiratsuka
Kaoru Hiratsuka
KMKazuaki Machioka
Kazuaki Machioka
HIHiroaki Iwamoto
Hiroaki Iwamoto
AMAtsushi Mizokami
Atsushi Mizokami
Understanding the mechanism of chemoresistance and disease progression in patients with prostate cancer is important for developing novel treatment strategies. In particular, developing resistance to cabazitaxel is a major challenge in patients with docetaxel‐resistant and castration‐resistant prostate cancer (CRPC) because cabazitaxel is often administered as a last resort. However, the mechanism by which cabazitaxel resistance develops is still unclear. C‐C motif chemokine ligands (CCL) were shown to contribute to the castration resistance of prostate cancer cells via an autocrine mechanism. Therefore, we focused on CCL as key factors of chemoresistance in prostate cancer cells. We previously established a cabazitaxel‐resistant cell line, DU145‐TxR/CxR, from a previously established paclitaxel‐resistant cell line, DU145‐TxR. cDNA microarray analysis revealed that the expression of CCL2 was upregulated in both DU145‐TxR and DU145‐TxR/CxR cells compared with DU145 cells. The secreted CCL2 protein level in DU145‐TxR and DU145‐TxR/CxR cells was also higher than in parental DU145 cells. The stimulation of DU145 cells with CCL2 increased the proliferation rate under treatments with cabazitaxel, and a CCR2 (a specific receptor of CCL2) antagonist suppressed the proliferation of DU145‐TxR and DU145‐TxR/CxR cells under treatments of cabazitaxel. The CCL2‐CCR2 axis decreased apoptosis through the inhibition of caspase‐3 and poly(ADP‐ribose) polymerase (PARP). CCL2 is apparently a key contributor to cabazitaxel resistance in prostate cancer cells. Inhibition of the CCL2‐CCR2 axis may be a potential therapeutic strategy against chemoresistant CRPC in combination with cabazitaxel.

1 April 2019 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
ILIrina Lerman
Irina Lerman
XMXiaoting Ma
Xiaoting Ma
CSChristina Seger
Christina Seger
AMAerken Maolake
Aerken Maolake
MGMaria de la luz Garcia-Hernandez
Maria de la luz Garcia-Hernandez
SHStephen R. Hammes
Stephen R. Hammes
Granulocytic myeloid infiltration and resultant enhanced neutrophil elastase (NE) activity is associated with poor outcomes in numerous malignancies. We recently showed that NE expression and activity from infiltrating myeloid cells was high in human prostate cancer xenografts and mouse Pten-null prostate tumors. We further demonstrated that NE directly stimulated human prostate cancer cells to proliferate, migrate, and invade, and inhibition of NE in vivo attenuated xenograft growth. Interestingly, reduced expression of SERPINB1, an endogenous NE inhibitor, also correlates with diminished survival in some cancers. Therefore, we sought to characterize the role of SERPINB1 in prostate cancer. We find that SERPINB1 expression is reduced in human metastatic and locally advanced disease and predicts poor outcome. SERPINB1 is also reduced in Pten-null mouse prostate tumors compared with wild-type prostates, and treatment with sivelestat (SERPINB1 pharmacomimetic) attenuates tumor growth. Knockdown of highly expressed SERPINB1 in nonmalignant prostatic epithelial cells (RWPE-1) increases proliferation, decreases apoptosis, and stimulates expression of epithelial-to-mesenchymal transition markers. In contrast, stable SERPINB1 expression in normally low-expressing prostate cancer cells (C4-2) reduces xenograft growth in vivo. Finally, EZH2-mediated histone (H3K27me3) methylation and DNA methyltransferase–mediated DNA methylation suppress SERPINB1 expression in prostate cancer cells. Analysis of The Cancer Genome Atlas and pyrosequencing demonstrate hypermethylation of the SERPINB1 promoter in prostate cancer compared with normal tissue, and the extent of promoter methylation negatively correlates with SERPINB1 mRNA expression. Implications: Our findings suggest that the balance between SERPINB1 and NE is physiologically important within the prostate and may serve as a biomarker and therapeutic target in prostate cancer.

8 March 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
KIKouji Izumi
Kouji Izumi
HIHiroko Ikeda
Hiroko Ikeda
AMAerken Maolake
Aerken Maolake
KMKazuaki Machioka
Kazuaki Machioka
TNTakahiro Nohara
Takahiro Nohara
MNMikio Namiki
Mikio Namiki

19 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
KIKouji Izumi
Kouji Izumi
AMAtsushi Mizokami
Atsushi Mizokami
HLHsiu-Ping Lin
Hsiu-Ping Lin
HHHui-Min Ho
Hui-Min Ho
HIHiroaki Iwamoto
Hiroaki Iwamoto
Wen-Jye LinWen-Jye Lin
Wen-Jye Lin
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer